OSCR Stock Recent News

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.

LOS ANGELES , Feb. 13, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Oscar Health, Inc. ("Oscar Health" or "the Company") (NYSE: OSCR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.

LOS ANGELES--(BUSINESS WIRE)--Oscar Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OSCR.

Oscar Health, Inc. (NYSE:OSCR ) Q4 2024 Earnings Conference Call February 4, 2025 5:00 PM ET Company Participants Chris Potochar – Vice President of Treasury and Investor Relations Mark Bertolini – Chief Executive Officer Scott Blackley – Chief Financial Officer Conference Call Participants Stephen Baxter – Wells Fargo Josh Raskin – Nephron Research Michael Ha – Baird Jonathan Yong – UBS Jessica Tassan – Piper Sandler Adam Ron – Bank of America Operator Good evening. My name is Rob, and I will be your conference operator today.

The U.S. healthcare sector has undergone a rapid digital transformation in recent years, driven by a combination of regulatory shifts, consumer demand and technological advancements. The pandemic accelerated the adoption of telemedicine, remote monitoring and artificial intelligence (AI)-driven diagnostics, making digital health an essential component of modern care delivery.

Oscar Health, Inc. (OSCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.66 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. “Oscar reported positive full year 2024 results, capping the strongest year of financial performance in Company history,” said Mark Bertolini, CEO of Oscar Health. “We reported both Adjusted EBITDA and net income profitability – two significant milestones. Our strong top.

In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $16.28, indicating a -0.12% shift from the previous trading day.

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $15.65, marking a -1.57% move from the previous day.

Oscar Health's targets of a 20% revenue CAGR through 2027 and 5% operating margin imply operating income around $700m in 3 years. Despite not being profitable yet, Oscar Health is projected to achieve GAAP profitability in FY24, with EPS expected to grow to $0.51 by FY25. The key risk is the repeal of ACA by the Trump administration, which would significantly impact the affordability of health insurance premiums for individual buyers.